DOCSLIB.ORG

Working with Industry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Working with Industry Working with Industry Delivering innovative research through effective partnerships Photograph © Rob Sparkes Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber Welcome to the NIHR CLAHRC YH Industry Briefing This briefing showcases not only our ways of working with industry partners but also how we are having an impact locally and nationally. The CLAHRC Vision is to understand health care and health service needs and how they can be addressed and transformed by digital technologies as we strive to achieve the three key aims of the NHS safety, quality and cost effective care (Delivering the benefits of Digital Health Care 2016) www.nuffieldtrust.org.uk/research/delivering-the-benefits- of-digital-health-care The new Government Green paper ‘Building Our Industry Strategy’ January 2017 www.gov.uk/ government/consultations/ building-our-industrial-strategy clearly identifies that a ‘modern industrial strategy is a critical part of our plan for post-Brexit Britain’ suggesting ‘a fairer society where wealth and opportunity are spread across every community in the United Kingdom not just the most prosperous places in London and the South East’. The Green paper proposes investment in science, research and innovation across all sectors through a new ‘Industry Strategy Challenge fund’. This view of a need to invest in applied health services and public health research in the populations most affected by disease burden and social deprivation was voiced recently in a letter entitled ‘shaping the future of NIHR’ from Professor Chris Whitty and Dr Louise Wood, with a clear view to balance NIHR research and innovation resources across the country. Both policy initiatives support the vision of our NIHR CLAHRC in Yorkshire and Humber where we have, for many years, sought to address health inequalities and the significant burden of chronic disease populations through the integration of new innovative digital technologies and in partnership with the medical technology sector. Our success and impact in this area is evidenced both by external evaluations, and also by ongoing feedback from the National Institute for Health Research (NIHR), which has commended us on our partnerships with patients, the public and industry. I am confident that our work with new and emerging technology, is helping us to address the chronic disease burden and social deprivation that is our Industrial Heritage legacy. Professor Sue Mawson Director, NIHR CLAHRC Yorkshire and Humber 1 Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber Background With the publication of: Our NIHR CLAHRC’s industry engagement enables the • ‘Innovation, Heath and Wealth: Accelerating private sector to capitalise on the great medical and adoption and diffusion in the NHS’ Department of clinical expertise housed within the region’s universities Health in Dec 2011 and research centres. We also seek to ensure patients have access to the latest research through our citizen • Academic Health Science Networks (AHSNs) cohorts enabling better outcomes for patients and a designation guidelines more person centre design and development focus. • Government Green paper ‘Building Our Industry Our range of offers to industry includes supporting: Strategy’ Jan 2017 • the development of partnerships between industry and the development of the Northern Health Science and NHS/Local Authorities Alliance www.thenhsa.co.uk, it has become even more apparent that the government’s wealth and growth • the implementation and evaluation of evidence agenda is clearly linked to closer partnerships between based technologies for chronic disease management the NHS, academia and industry. and end of life care In Yorkshire and Humber our portfolio includes a range • access to health economics research and new of high value, high trust industrial collaborators from models of care using existing technologies global, national small and medium-sized enterprises • validation of technology need through stakeholder (SMEs). Our focus has been to work with industrial scoping partners that align with our research themes and our • the contextualising of existing technologies for core objectives; hence we have focussed more on different environments the medical device and technology sector, and on delivering the benefits of digital health care. Given that • use of participatory design methodologies in the Pharma sector is beginning to explore the role of partnership with industry medical devices within its portfolio of service offerings, • applications for new funding streams for we will keep a watching brief for potential future partnerships and Knowledge Transfer with industry partners. Each of these activities helps to ensure that the NHS The medical technology market is estimated to be and Local Authorities have access to technology worth £150-170bn worldwide, with growth rates solutions. Therefore enabling a transformation in forecast at 10% a year over the next five years and a the way they work to improve the quality, safety, market size approaching £300bn by 2015. It is a sector productivity and cost effectiveness of care. For industry that is growing rapidly in the UK, with more than 3,000 these initiatives help ensure that their products and companies that generate around £15bn in turnover services address real needs and that their solutions are http://bit.ly/2m2skUW. fit for purpose and affordable. Yorkshire and Humber is perfectly positioned for growth - with NHS England based in this region, a strong base of medtech and technology enabled care firms and coterminous NIHR CLAHRC YH and the YH AHSN resources to spearhead the use of innovative products and services in the NHS. The NHS Five Year Forward View (5YFV) and National Information Board’s paper on Personalised Health and Care 2020 highlight that digital technology plays a key role in all three elements in the 5YfV: public health, quality of care and efficiency. It will help ensure best value for the tax payer. More importantly these policy documents also state digital technologies will be more tightly embedded in NHS policy, finance and regulation. Delivering innovative research through effective partnerships 2 Objectives NHS England recognises that without the effective This is not to say that we will not engage with a much use of new technologies the NHS will fail to deliver broader range of industry representatives. We see on its commitments in years to come. With this in the relationships with our stakeholders as being vital mind, NIHR CLAHRC YH has developed an Industry to our impact agenda, raising awareness of the full Strategy that focuses on the medtech and medical range of NIHR CLAHRC YH activities, our core mission devices sector. We believe this is the area that has the and underlying principles. Engaging with industry most potential to change the nature of health care, and community is a dialogue. A key feature of our promoting wealth, improving health and building on ambition is for NIHR CLAHRC YH to increasingly act as the extensive work in this sector over the past five a ‘meeting place’ and facilitator for industry and other years in YH and within our partner organisations. stakeholders with an interest in mutual interaction, but By wealth, we mean the impact our collaboration who would not readily come into contact with each can have working with industry to support the other or with leading academic researchers. implementation of a cost effective health service We have close relationships with both the YH AHSN through new models of care and the integration of and the Devices for Dignity (D4D) Health Technologies digital capabilities into new care pathways. This is Co-operative (HTC). Collaboration with the YH AHSN alongside the direct benefits of attracting research has included the development of an evaluation funding and industry into the region. offer for the Vanguards and the sustainability and NIHR CLAHRC YH measures the success of its transformation plans (STPs), thereby supporting new industry engagement on building a small number government policies regionally. From an industry of very high value relationships. We work closely perspective the link between the YH AHSN and with a wide range of collaborators to identify and NIHR CLAHRC YH is through the Telehealth and Care understand industry needs, match industry needs Technology Theme. The collaboration with D4D, with academic research interests and capability, also hosted at Sheffield Teaching Hospitals NHS FT, whilst managing our established partnerships to allows us to work together on the innovation pathway ensure mutually beneficial and successful outcomes. directing industry partners accordingly. 3 Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber CLAHRC Match linked to Financial Model industry 2015/2016 CLAHRCs were the first NIHR initiative that followed Proportion of match by source the Canadian model of health academies (Lomas, J., 2007. The in-between world of knowledge brokering. BMJ: British Medical Journal, pp.129-132) with a Charitable sector matched funding requirement to build on the funding Local authorities provided by the NIHR contract. The match funding Industry needs to be at least to the level of the NIHR award (match £ for £), each CLAHRC needing to achieve The NHS a portfolio of £10 million match over the five year Universities period in order to drawdown funds from NIHR. This model offers the opportunity for collaborating organisation to provide match funding
Load more

Recommended publications
  • Leicester, Leicestershire and Rutland (LLR) Local Digital Roadmap 2016 - 2021 Contents
    Leicester, Leicestershire and Rutland (LLR) Local Digital Roadmap 2016 - 2021 Contents Foreword for Local Digital Roadmap 2 5. Capabilities 38 5.1 Paper free at Point of Care groups 1. Introduction 4 of capabilities 38 1.1 Our Journey in Delivering the 5.1.1 Records, assessments and plans 38 Five Year Forward View and Personalised 5.1.2 Transfers of care 41 Health and Care 2020 4 5.1.3 Orders and results management 43 1.2 Overview of Organisations Covered 6 5.1.4 Medicines management and optimisation 43 1.3 Sustainability and Transformation Plan 5.1.5 Decision support 45 (STP) Alignment 6 5.1.6 Remote care 46 1.3.1 Better Care Together (BCT) 7 5.1.7 Asset and resource optimisation 49 1.4 Leicester, Leicestershire and Rutland (LLR) 5.2 16/17-17/18 Universal capabilities 54 Context 8 5.3 Capabilities Delivery Plan 55 2. A vision for digitally-enabled 6. Information Sharing 56 transformation 19 6.1 Information Sharing Strategy 56 6.2 Information Governance 56 6.3 Interoperability Strategy 57 3. Baseline Position 20 3.1 Current Technology Landscape 20 7. Infrastructure 58 3.1.1 Data Sharing 20 3.1.2 Patient Access 21 3.1.3 Electronic Prescriptions 21 8. Minimising risks arising from 3.1.4 Electronic Clinical Correspondence 21 technology 63 3.1.5 Business Intelligence 21 3.1.6 System Access 22 9. Timescales and Delivery of the 3.1.7 Pathways 22 Local Digital Roadmap 64 3.1.8 Patient Focused Apps 22 2016/17 64 3.2 Rate limiting factors 23 2017/18 66 2018/19 68 4.
    [Show full text]
  • Board of Directors
    Board of Directors Time: 1310-1430 hours Venue Date: Wednesday, 31 October 2018 Room 3, 3rd Floor, Unit 2 (Battersea Studio 2), Battersea, London SW8 3HR1 Presenters are reminded to provide a succinct and focused introduction, highlighting the key questions and only things which have changed since the preparation of the report 1 Administrative and other priority items 1.1 Welcome, introduction and apologies: Angela Greatley Verbal 1310 2 1.2 Patient story Hilder Dewa Verbal 1.3 Written questions from the public3 Angela Greatley Verbal 1.4 Interests relevant to the agenda to declare and any new Angela Greatley Verbal interests 1.5 Minutes of meeting held on 20.09.18 and Angela Greatley Pages 3 - 4 27.09.18 Pages 5 - 9 1.6 Matters arising and action log Angela Greatley Page 10 1.7 Chair’s report Angela Greatley Pages 11 - 13 1.8 Chief Executive’s report Andrew Ridley Pages 14 - 23 1.9 Quality report – Q2 Charlie Sheldon Pages 24 - 79 2 Strategic items 2.1 Operational plan 2019/20 – timescales and planned Mike Fox Pages 80 - 91 1335 approval process / dates 2.2 Clinical strategy – refresh – aligned to organisational Joanne Medhurst Pages 92 - 105 strategy – agreed in March 2017 3 Operational items 3.1 Integrated finance and performance report M6 Mike Fox Pages 106 - 127 1350 Jitesh Chotai To be provided 3.1.1 FRIC report, 29.10.18 separately 4 3.2 Learning from deaths – Q2 report Joanne Medhurst Pages 128 - 131 3.3 Health and safety policy - Q2 report Elizabeth Hale Pages 132 - 151 3.4 STP / Partnerships update – Q2 report James Benson Pages
    [Show full text]
  • The World's Leading AI in Medicine Summit
    The world’s leading AI in medicine summit Wednesday 5th February 2020 London, UK http://www.intelligenthealth.ai/ The mission? Intelligent Health, in partnership with NHSX, will bring the global AI and health community to London in February 2020 for a one-day event to advance discussions on how to apply AI and drive technological collaboration in healthcare. 800+ delegates will join industry leading global speakers for an in-depth look at AI within the UK health market, how it can be used to prevent and solve some of the world’s greatest healthcare problems, improve the health of the human race and set the UK AI agenda in healthcare for 2020 and beyond. What’s on? Jam-packed day of health tech goodness! Practical, real-world AI use cases, announcements from tech giants, hear from health tech transformers of tomorrow and a showcase of innovation, followed by 10 collaborative hands-on sessions tackling live digital health challenges. Be ready to think like a physician and code like a developer. Wednesday 5th February 2020 07:30 REGISTRATION Session One 09:00 – 11:00 09:00 WELCOME Inspired Minds Denise Tack, Strategy Director - Health, Inspired Minds WELCOME NHSX Tara Donnelly, CDIO, NHSX WELCOME and chairperson’s opening remarks Sameena Ali-Khan, Television Presenter, ITV 09:20 HEADLINER Leading digital change, interoperability and innovation – how the NHS will work more effectively with larger tech firms and digital health innovators Tara Donnelly, CDIO, NHSX 09:45 HEADLINER Maximising our digital infrastructure for a 21st century workforce Frank Hester, Founder and CEO, The Phoenix Partnership 10:10 HEADLINER Inside Pandora's Black Box: Understanding decision-making in diagnostic AI and its implications for clinician skills Dr.
    [Show full text]
  • Management Stakeholders
    Hyperglycaemia in acute coronary syndromes: management Stakeholders 15 Healthcare 2gether NHS Foundation Trust 3M Health Care UK 4Children 5 Boroughs Partnership NHS Foundation Trust A.Menarini Pharma U.K. S.R.L. Abbott Diabetes Care Abbott Diagnostics Division Abbott Diagnostics Division Abbott Laboratories Abbott Vascular Devices Abbott Vascular Devices AbbVie AbbVie Abertawe Bro Morgannwg University NHS Trust Achieving for Children Action Heart Action on Addiction Action on Hearing Loss Action on Smoking & Health Action on Smoking and Health Addaction Addenbrookes Hospital Addiction Today ADFAM Adults Strategy and Commissioning Unit Advisory Committee for Community Dentistry Advisory Council on the Misuse of Drugs Afiya Trust African Health Policy Network Aintree University Hospital NHS Foundation Trust Alcohol and Drug service Alcohol Focus Scotland Alcohol Use Disorders: Clinical Management Guideline Development Group Alcoholics Anonymous Alder Hey Children's NHS Foundation Trust Alere Alere Alere International Alere Ltd Alere Ltd Alkermes Inc All Party Parliamentary Group on Vascular Disease Allergan Ltd UK Alliance Boots plc Allocate Software PLC Alpha Medical American Medical Systems Inc. American Medical Systems Inc. American Medical Systems UK Ltd AMORE health Ltd AMORE health Ltd AMORE Studies Group AMORE Studies Group Aneurin Bevan University Health Board anglia community leisure Anglia University Anglian Community Enterprise Ark Therapeutics Ltd Arrhythmia Alliance Arrowe Park Hospital Assocation of NHS Occupational Physicians
    [Show full text]
  • Hydroxychloroquine for Prevention of COVID-19 Mortality: a Population-Based Cohort Study
    medRxiv preprint doi: https://doi.org/10.1101/2020.09.04.20187781; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study Christopher T Rentsch1*&, Nicholas J DeVito2*, Brian MacKenna2*, Caroline E Morton2*, Krishnan Bhaskaran1, Jeremy P Brown1, Anna Schultze1, William J Hulme2, Richard Croker2, Alex J Walker2, Elizabeth J Williamson1, Chris Bates3, Seb Bacon2, Amir Mehrkar2, Helen J Curtis2, David Evans2, Kevin Wing1, Peter Inglesby2, Rohini Mathur1, Henry Drysdale2, Angel YS Wong1, Helen I McDonald1, Jonathan Cockburn3, Harriet Forbes1, John Parry3, Frank Hester3, Sam Harper3, Liam Smeeth1, Ian J Douglas1, William G Dixon4, Stephen JW Evans1, Laurie Tomlinson1†, Ben Goldacre2† 1 Electronic Health Records Research Group, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT 2 The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Woodstock Rd, Oxford OX2 6GG 3 The Phoenix Partnership, 129 Low Lane, Horsforth, Leeds LS18 5PX 4 Centre for Epidemiology Versus Arthritis, The University of Manchester, Oxford Road, Manchester M13 9PL *These authors contributed equally to this work †Joint principal investigators &corresponding: [email protected]; @DarthCTR NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.09.04.20187781; this version posted September 9, 2020.
    [Show full text]
  • 2901121 Safer Hospitals, Safer Wards
    The NHS England Putting business plan for Patients First 2013/14 – 2015/16 SUPPORTING, DEVELOPING AND ASSURING THE DIRECT COMMISSIONING COMMISSIONING SYSTEM PARTNERSHIP STRATEGY, FOR RESEARCH Achieving an AND SAFER HOSPITALS INNOVATION integrated digital FOR OUTCOMES SAFER WARDS careEMERGENCY record AND PREPAREDNESS QUALITY GROWTH WORLD WORLD CLASS CLASS CUSTOMER CLINICAL SERVICE: DEVELOPING AND INFORMATION, CUSTOMER PROFESSIONAL TRANSPARENCY COMMISSIONING AND SUPPORT SERVICE: LEADERSHIP PARTICIPATION UNITS INFORMATION, PEOPLE ACCESSING TRANSPARENCY THEIR AND DATA PARTICIPATION RIGHT DATA, NHS NUMBER: RIGHT PLACE, RIGHT TIME INTEGRATING CARE COMMUNITY OF PRACTICE High quality care for all, now and for future generations NHS England INFORMATION READER BOX Directorate Medical Operations Patients and Information Nursing Policy Commissioning Development Finance Human Resources Publications Gateway Reference: 00201 Document Purpose Guidance and launch of the Safer Hospitals, Safer Wards Technology Fund Document Name Safer Hospitals, Safer Wards: Achieving an Integrated Digital Care Record Author NHS England Publication Date 01 July 2013 Target Audience Foundation Trust CEs, Foundation Trust Board Chairs, NHS Trust CEs, NHS Trust Board Chairs, Medical Directors, Directors of Nursing, Directors of Finance, NHS England Regional Directors, NHS England Area Directors Additional Circulation List CCG Clinical Leaders, CCG Accountable Officers, CSU Managing Directors, Local Authority CEs, Directors of Adult SSs, Academic Health Science Networks Description This document sets out the benefits case for adopting safe digital record keeping as a precursor to achieving integrated digital care records across the health and care system. It provides further details and support for NHS Trusts, including Foundation Trusts, relating to their progress from paper to paper-light and ultimately paperless record keeping.
    [Show full text]
  • Stroke (QS Update) Stakeholders 3M Health Care UK Abbott Molecular
    Stroke (QS update) Stakeholders 3M Health Care UK Abbott Molecular Abertawe Bro Morgannwg University Health Board Acupuncture Association of Chartered Physiotherapists Adults Strategy and Commissioning Unit African Health Policy Network Age Related Diseases and Health Trust Age UK AGILE: Chartered Physiotherapists working with Older People Aintree University Hospital NHS Foundation Trust Airedale NHS Trust Alder Hey Children's NHS Foundation Trust All Wales Stroke Dietitians Group Allergan Ltd UK Allocate Software PLC AMORE health Ltd AMORE Studies Group Anglia Stroke and Heart Network Anglian Community Enterprise AntiCoagulation Europe Anticoagulation Specialist Association Apetito Ltd Applied Medical Applied Medical UK Ltd Arrhythmia Alliance Arrowe Park Hospital Association for Continence Advice Association for Dance Movement Psychotherapy UK Association of Ambulance Chief Executives Association of Anaesthetists of Great Britain and Ireland Association of British Healthcare Industries Association of British Insurers Association of British Neurologists Association of Chartered Physiotherapists in Neurology Association of Clinical Pathologists Association of Dance Movement Therapy UK Association of Directors of Adult Social Services Association of Optometrists Association of Professional Music Therapists Astrazeneca UK Ltd Atrial Fibrillation Association Autism in Mind Avon, Gloucestershire and Wiltshire Strategic Health Authority Bard Limited Barnsley Hospital NHS Foundation Trust Bayer HealthCare Bayer plc Bedfordshire and Hertfordshire
    [Show full text]
  • Board Meeting
    Board Meeting A virtual meeting will be held Wednesday, 29 July 2020 commencing at 1:00pm If you are unable to attend please notify Keith Eales on 01202 277008. Yours sincerely, Andy Willis Chairman PART 1 Lead Paper Time 1 Apologies AW Verbal 1:00 2 Declarations of interests in relation to agenda AW Verbal items 3 Patient Story TP Paper 4 Minutes: 24 June 2020 - to approve AW Paper 5 Matters Arising – to review progress AW Paper 6 Chairman’s Report - to receive an update. AW Verbal Strategy Items 7 Fit for the Future Programme KD Paper To note the report. Current Affairs and Operational Performance 8 Chief Executive’s Report EY Verbal 1:45 To note the update. 9 Trust Board Integrated Corporate Dashboard KD Paper 2:00 To note performance for June. 10 Trust Finance Report for June 2019 MM Paper 2:15 To the report. 1 11 Dorset Care Record Update MM Paper 2:30 To note the report. Regulatory and Governance Matters 12 Reports from Committee Chairs 2:40 a) Appointments and Remuneration AW Verbal Committee: 8 July 2020 b) Mental Health Legislation Assurance SM Paper Committee: 8 July 2020 c) Audit Committee: 15 July 2020 TP Paper d) Quality Governance Committee:15 DB Paper July 2020 13 Annual Report of the Mental Health SM Paper 2:50 Legislation Assurance Committee 2019/20 To note the report. 14 Appointment of a Senior Independent AW Paper 3.00 Director To make an appointment. Other Matters 15 Questions from Governors on matters on the AW Verbal agenda What went well, what could be better? 15 Next Meeting: 1.00pm, Wednesday 30 AW Verbal 3:20 September 2020 2 Agenda Item 3 Patient Story Part 1 Board Meeting 29 July 2020 Author Janine Coletta, Patient Experience Facilitator Purpose of Report To consider the patient experience of our service Executive Summary The report is being submitted to the Board for consideration, reflection and to highlight the positive experience of care received from Langdon Ward (now Colmers Ward) at Bridport Hospital, and how this has impacted both the patient and the patient’s family.
    [Show full text]
  • 23 November 2020 Special Meeting Board of Trustees - 1
    23 November 2020 Special Meeting Board of Trustees - 1 REPORTS OF THE BOARD OF TRUSTEES The following reports were presented by Russ Kridel, MD, Chair: 1. 2019 GRANTS AND DONATIONS Informational report; no reference committee hearing. HOD ACTION: FILED This informational financial report details all grants or donations received by the American Medical Association during 2019. American Medical Association Grants & Donations Received by the AMA For the Year Ended December 31, 2019 Amounts in thousands Amount Funding Institution Project Received Agency for Healthcare Research and Quality Midwest Small Practice Care Transformation Research $ 4 (subcontracted through Northwestern University) Alliance Agency for Healthcare Research and Quality Health Insurance Expansion and Physician Distribution 49 (subcontracted through RAND Corporation) Centers for Disease Control and Prevention Engaging Physicians to Strengthen the Public Health 18 System and Improve the Nation's Public Health Centers for Disease Control and Prevention Building Healthcare Provider Capacity to Screen, Test, 182 (subcontracted through American College of Preventive and Refer Disparate Populations with Prediabetes Medicine) Centers for Disease Control and Prevention Preventing Heart Attacks and Strokes in Primary Care 117 (subcontracted through National Association of Community Health Centers, Inc.) Centers for Medicare & Medicaid Services Transforming Clinical Practices Initiative — Support 467 and Alignment Networks Government Funding 837 American Heart Association, Inc.
    [Show full text]
  • BOT Report 02-Nov-20.Docx
    REPORT OF THE BOARD OF TRUSTEES B of T Report 2, November 2020 Subject: Update on Corporate Relationships Presented by: Russ Kridel, MD, Chair 1 PURPOSE 2 3 The purpose of this informational report is to update the House of Delegates (HOD) on the results of 4 the Corporate Review process from January 1 through December 31, 2019. Corporate activities that 5 associate the American Medical Association (AMA) name or logo with a company, non-Federation 6 association or foundation, or include commercial support, currently undergo review and 7 recommendations by the Corporate Review Team (CRT) (Appendix A). 8 9 BACKGROUND 10 11 At the 2002 Annual Meeting, the HOD approved revised principles to govern the American Medical 12 Association’s (AMA) corporate relationships, HOD Policy G-630.040 “Principles on Corporate 13 Relationships.” These “Guidelines for American Medical Association Corporate Relationships” were 14 incorporated into the corporate review process, are reviewed regularly, and were reaffirmed at the 15 2012 Annual Meeting. AMA managers are responsible for reviewing AMA projects to ensure they 16 fit within these guidelines. 17 18 YEAR 2019 RESULTS 19 20 In 2019, 85 new activities were considered and approved through the Corporate Review process. Of 21 the 85 projects recommended for approval, 47 were conferences or events, 10 were educational 22 content or grants, 23 were collaborations or affiliations, two were member programs, one was an 23 American Medical Association (AMA) Alliance activity and two were American Medical 24 Association Foundation (AMAF) programs (Appendix B). 25 26 CONCLUSION 27 28 The Board of Trustees (BOT) continues to evaluate the CRT review process to balance risk 29 assessment with the need for external collaborations that advance the AMA’s strategic focus.
    [Show full text]
  • Cohort Study in Opensafely Using Linked Primary Care, Secondary Care and Death Registration Data
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.16.21260628; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 1 2 Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: 3 cohort study in OpenSAFELY using linked primary care, secondary care and death registration data 4 5 Krishnan Bhaskaran PhD1* (corresponding: [email protected]), Christopher T Rentsch 6 PhD1*, George Hickman BEng2*, William J Hulme PhD2*, Anna Schultze PhD1, Helen J Curtis DPhil2, 7 Kevin Wing PhD1, Charlotte Warren-Gash PhD1, Laurie Tomlinson PhD1, Chris J Bates PhD3, Rohini 8 Mathur PhD1, Brian MacKenna MPharm2, Viyaasan Mahalingasivam MRCP1, Angel Wong PhD1, Alex J 9 Walker PhD 2, Caroline E Morton MRCGP2, Daniel Grint PhD1, Amir Mehrkar MRCGP2, Rosalind M 10 Eggo PhD1, Peter Inglesby MPhil2, Ian J Douglas PhD1, Helen I McDonald PhD1, Jonathan Cockburn 11 BSc3, Elizabeth J Williamson PhD1, David Evans MPhil2, John Parry MRCGP3, Frank Hester BSc3, Sam 12 Harper MSc3, Stephen JW Evans MSc1, Sebastian Bacon BA2, Liam Smeeth PhD1+, Ben Goldacre 13 MRCPsych2+ (* = contributed equally; + = joint senior authors) 14 1 – Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine; 15 2 - The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, 16 UK; 3 – The Phoenix Partnership, TPP House, Horsforth, Leeds, UK 17 18 ABSTRACT 19 Background: There is concern about medium to long-term adverse outcomes following acute 20 COVID-19, but little relevant evidence exists.
    [Show full text]
  • Suboptimal Prescribing Behaviour Associated with Clinical Software Design Features: a Retrospective Cohort Study in English NHS Primary Care
    Research Brian MacKenna, Helen J Curtis, Alex J Walker, Seb Bacon, Richard Croker and Ben Goldacre Suboptimal prescribing behaviour associated with clinical software design features: a retrospective cohort study in English NHS primary care Abstract INTRODUCTION care prescribing in England’s prescribing Electronic health record (EHR) systems are data (Box 1), where prescriptions that were Background Electronic health record (EHR) systems are used by clinicians to record patients’ medical apparently prescribed generically had been used by clinicians to record patients’ medical information, and to support clinical activities charged above the standard NHS tariff information, and support clinical activities such as such as prescribing or test ordering. prices, amounting to an estimated excess prescribing. In England, healthcare professionals There is limited literature describing how cost of more than £9.5 million per annum. are advised to ‘prescribe generically’ because generic drugs are usually cheaper than branded EHR system design features can impact The authors discovered they were not ‘true’ alternatives, and have fixed reimbursement costs. on clinical practice. However, this typically generic items and so termed the items ‘Ghost-branded generics’ are a new category uses indirect evidence: qualitative research responsible ‘ghost-branded generics’. A of medicines savings, caused by prescribers ghost-branded generic is prescribed and specifying a manufacturer for a generic product, observing or interviewing clinicians; often resulting in a higher reimbursement price questionnaires interrogating clinicians about dispensed where a prescriber selects compared with the true generic. their experiences of EHRs; or descriptive a generic product but specifies the Aim analyses of clinicians’ spontaneous reports manufacturer, usually inadvertently. In To describe time trends and practice factors of errors and safety issues.1–3 There has such cases, the pharmacy is reimbursed associated with excess medication costs from ghost-branded generic prescribing.
    [Show full text]